Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.

Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.

Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.

Conny Bogentoft, CEO of Karolinska Development, said, "The completion of the Dilafor Phase II trial is an important step for Karolinska Development and we are extremely pleased that Dilafor has achieved some very positive results. At the same time, it also goes a long way towards validating our business model. We are now very much focused on finding commercial opportunities for Dilafor's tafoxiparin and for several of our other projects that are reaching maturity."

The tafoxiparin Phase II trial was designed to measure the effect on labor time after preventive treatment using the candidate drug. 263 women at 18 clinics in Sweden were included in a randomized, double-blind and placebo-controlled study, conducted over a two year period. The treatment, which was administered during the last phase of pregnancy, was shown to be safe and well tolerated. In the groups as a whole the labor time was shorter in the treated group, but did not reach statistical significance.

However, further analyses of results suggest that treatment with tafoxiparin provides beneficial effects, including: a statistically significant (p=0.04) reduction in the number of women with labor times in excess of twelve hours; fewer complications as a cause of protracted labor; and fewer caesarean sections as a result of protracted labor.

Dilafor's CEO, Anders Asell, commented, "By concluding this proof-of-concept study we have shown that tafoxiparin has the potential to solve an important unmet medical need. We will now start actively seeking a collaboration partner with whom we can carry out a Phase III program. Parallel to this we will continue to develop tafoxiparin within Dilafor."

About Dilafor AB

Established in 2003, Dilafor AB is a Swedish R&D company focused on developing pharmaceutical products from heparin derivatives with low anticoagulant activity. The company has a balanced product portfolio representing highly promising ideas and innovations. Each of the projects addresses important and unmet medical needs.

The project, tafoxiparin (DF01) for protracted labor, successfully concluded a clinicial Phase II study in July 2009. DF02, a drug candidate for the treatment of severe malaria, is presently in Phase I clinical development.

Dilafor is managed by senior staff with high academic credentials and extensive industrial experience gained from key areas of pharmaceutical development. The company is located at Karolinska Institutet Science Park and is part of Karolinska Development.

About Karolinska Development AB

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development AB is a new type of company focused on filling the innovation gap within the pharmaceutical industry. Using a unique, highly cost-effective model Karolinska Development commercializes internationally renowned life science innovations, helping to deliver the medical products of the future.

    For more information, contact:

    Conny Bogentoft, CEO, Karolinska Development AB
    Cell phone +46-70-668-61-43
    info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) ... phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, ...
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
(Date:2/10/2016)... Feb. 10, 2016  Matchbook, Inc., a company ... growing biotech companies, announced today the appointment of ... Advisor. Jim brings nearly 25 years of experience ... having spent nearly two decades in executive level ... Procurement at Genzyme and, most recently headed global ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a research registry built on the secure online PatientCrossroads platform, has exceeded both ... 1,600 participants have joined the PROMPT study, which seeks to advance understanding of ...
Breaking Biology Technology:
(Date:2/8/2016)... Republic , February 8, 2016 ... global payment platform which presents innovation for clients, ... Authentication feature called VoiceKey. --> Worldcore ... which presents innovation for clients, comfort and unbeatable ... VoiceKey. --> Worldcore is ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... 3, 2016 --> ... report "Automated Fingerprint Identification System Market by Component (Hardware ... (Banking & Finance, Government, Healthcare, and Transportation) and Geography ... market is expected to be worth USD 8.49 Billion ... 2015 and 2020. The transformation and technology evolution from ...
Breaking Biology News(10 mins):